Background: Depressive disorders may affect up to 50% of patients with Parkinson disease (PD) and are associated with increased disability and reduced quality of life. No previous study has systematically examined the impact of depressive symptoms in early, untreated PD.
part of the clinical trials (FS1 and FS-TOO), study investigators further evaluated subjects who scored Ն5 on the GDS-15, to assess for clinically significant depression or suicidal ideation and determine the need for either psychiatric consultation or antidepressant therapy. These outcomes (referral, antidepressant therapy) were recorded at the visit in which a patient screened positive for depression. We also used the concomitant medication log to assess whether a patient was ever prescribed antidepressants during the study for the indication of depression or depression/anxiety. We analyzed the GDS-15 as a dichotomous variable, Ͻ5 or Ն5, because of the reported accuracy for detecting major and minor depression in PD. 12 Therefore, while a SCID was not performed, we use the term depression to refer to those who screened positive and have either depressive disturbances or less well-defined depressive symptoms.
The other clinical outcome measures collected included parts I to III of the Unified PD Rating Scale (UPDRS) and the Hoehn and Yahr (H&Y) Staging Scale for PD severity and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) for cognition. 15 The primary outcome of the clinical trials was change in total UPDRS scores from baseline until investigators determined that the subject needed symptomatic therapy due to disability from PD symptoms.
Statistical models. Linear regression (mixed effect) was
used to model repeated visits of ADLs, as measured by part II of the UPDRS, and motor function, as assessed by part III of the UPDRS. The independent variables included in each model were study treatment group, age at baseline, gender, length of follow-up, determination of need for symptomatic therapy for PD, and repeated visits of clinical measures including the GDS-15 Ն5, RBANS change from baseline, and part III of the UPDRS change from baseline (only used for ADL model). These two mixed effect linear regression models included a random effect for subject, which takes into account the repeated measures among subjects.
To evaluate the role of depression on the need for symptomatic therapy, we used a time-dependent Cox regression to model the time to the need for symptomatic therapy (dependent variable). The covariates included in the model were study treatment group, age at baseline, gender, repeated visits of GDS-15 Ն5, total UPDRS change from baseline, RBANS change from baseline, and H&Y change from baseline. The latter four were time-varying covariates. The timedependent Cox regression is an extension of ordinary Cox proportional hazard regression, adapted for covariates that vary over time for the same individuals. The assumption of proportional hazards over time is relaxed.
RESULTS
Baseline frequency and incidence of depression. Baseline demographics and depression status are shown in table 1. Of the 413 participants, 101 (24.5%) reported a history of depression. Fifty-seven (13.8%) participants had a GDS-15 score Ն5 at baseline. Compared to nondepressed subjects, subjects who screened positive for depression had more severe PD measured by UPDRS scores (p Ͻ 0.01), but were at comparable H&Y stages. At baseline, 46 participants (11%) were receiving antidepressants for the treatment of depression. During the average 14.6 months of follow-up, there were 57 (16%) incident cases of depression (GDS-15 Ն5) among subjects who were not depressed at baseline. Overall, 114 of the 413 (27.6%) subjects experienced depression during the study. The median GDS score among subjects who screened as depressed was 6, reflecting a mild level of depressive symptoms.
Of the 114 patients who screened positive for depression, 28 (25%) were already receiving treatment for their depression, but had persistent depressive symptoms. Forty subjects (35%) were started on antidepressant therapy or referred for psychiatric evaluation at the time of the screening or later in the study. However, 46 participants (40%) were never treated with antidepressants nor referred for psychiatric evaluation. More severely depressed subjects were more likely to be treated. Among the 57 incident cases of depression, 8 of 52 participants (15%) with GDS between 5 and 9 (mild) compared with 4 of 5 participants (80%) with GDS Ͼ9 (moderate to severe) were either started on pharmacologic therapy for their depression or referred for a psychiatric evaluation at that visit. Impact of depression on function and initiation of symptomatic therapy. We assessed the impact of depression scores on measures of motor function 
DISCUSSION
This study assessed the impact of depression in early, untreated PD. We used data from two clinical trials, controlling for treatment assignments and other covariates. There are three main findings. First, depression is common in this cohort, whether by self-report or by a quantitative measure of depressive symptoms using the GDS-15. A total of 114 (27.6%) subjects had clinically significant, generally mild depressive symptoms during the study. Second, 40% of those who screened positive by the GDS-15 did not receive antidepressants or psychiatric referral. Third, depressive symptoms are associated with clinically important impairments in ADLs and increase the likelihood of starting on medications for PD. The effect of depression on ADL scores is comparable to the effect seen with an increase of six points on the motor section of the UPDRS (table 3) . Additionally, the presence of depression, even when controlling for impaired motor function, contributes to the clinician's assessment of the need to initiate symptomatic therapy for PD.
Reported prevalence and incidence rates for depression in PD are highly variable. 16 This is in part due to different assessment techniques and populations. In this study, we used a validated screening instrument, the GDS-15, rather than a diagnostic interview. In a study using the Beck Depression Inventory (BDI) with a cutoff of Ն10, 44% of a clinic population screened positive for clinically important depressive symptoms. 9 In a similar, clinic convenience sample, 34% of patients met DSM-IV criteria for major or minor depression. 8 Both of these studies were conducted in established PD cases with an average H&Y score of approximately 2.5 and PD duration of over 7 years. The slightly lower point prevalence rates for depression in our study compared to other studies may be due to the particular PD population, which had a mean duration since diagnosis of PD of only 7.9 (10.0) months, or the screening instrument. Importantly, while this is a large cohort, this is not a population-based sample. Prevalence and incidence estimates in a clinical trial cohort may not be generalizable.
Previous clinic-based studies showed high rates of under-recognition and undertreatment of symptoms of depression in PD. 8, 9 In the study by Weintraub et al., 8 almost two thirds of subjects meeting criteria for depression were not treated. Similarly, studies by Richard and Kurlan 17 and Shulman et al. 9 found that clinicians did not recognize or treat depression in 50% or more of dPD patients. Our findings are consistent with depression screening efforts in the primary care literature which suggest that up to 60% of patients may be correctly identified as depressed and treated. 18 However, as seen in this study, many treated patients remain depressed and may require more intensive psychiatric treatment.
Subjects with moderate to severe depression (GDS-15 Ͼ 9) were more likely to receive treatment or referral than those with mild depression (GDS-15 between 5 and 9). This suggests that most cases of dPD fall below the threshold of clinical intervention. In addition to overlap with PD symptoms, dPD may go untreated because it is mild and not thought to require antidepressant or other interventions. Additionally, less evidence is available to support treatment of minor depression in the elderly, as compared to major depression. 19 As suggested by this study, dPD is largely comprised of minor depression. 1, 20 In a community-based study using the Montgomery and Asberg Depression Rating Scale, Tandberg et al. found that 5.1% of patients with PD were moderately to severely depressed, whereas 45.5% of the cohort had mild depressive symptoms. 2 That being said, mild depressive disturbances are associated with reduced functional ability, 4, 21 increased caregiver burden, 22 and reduced quality of life. 6 Evidence suggests that the detection and treatment of mild depressive symptoms in PD may improve these outcomes. 7, 16, [23] [24] [25] There are other potential explanations for the gap between the GDS-15 screening and the subsequent lack of treatment of depression. First, the GDS-15 may not be a valid instrument for identifying clinically significant depressive disturbances in newly diagnosed patients with PD, or different cutoff scores may be applicable to this population. Because this study did not use DSM criteria or a standardized interview such as the SCID, we cannot ensure the diagnostic accuracy of psychiatric disturbances of the screening instrument or the movement disorders specialist. However, the GDS-15 has been validated in both the elderly 26 and in a range of patients with PD 12,13 with good accuracy for major and minor depression. Second, investigator clinical behavior may be different in a clinical trial setting compared to clinical practice. However, an explicit effort was made in these clinical trials to screen for depression and allow for the provision of appropriate care; antidepressants were not restricted medications and most subjects with moderate to severe depression were treated. These findings raise the concern of limited recognition and treatment of clinically significant depressive symptoms in PD, even in the setting of a screening effort with a validated, self-report instrument, at movement disorders centers.
The relationship between motor impairment and depression is complicated. Subjects who screened positive for depression had more impairment at baseline on both ADL and motor sections of the UPDRS. This finding is not surprising and is consistent with other studies [3] [4] [5] 27 and the idea that dPD is a reflection of more extensive PD pathology, such as more cell loss in the ventral tegmental area. 20, 28, 29 Over time, depression scores were independently associated with increased impairment in ADLs, but were not significantly associated with increased motor impairment. Previous studies have found that depression was associated with greater motor progression 5, 30 and impairments in fine motor skills. 31 However, regression analyses were not used in these studies to isolate the effects of depression on motor progression from other confounding variables. 5, 30 Over time, it appears that depression does not actually influence the progression of motor signs, but increases the disability associated with a given level of motor manifestations of PD. Depression scores were significantly associated with the clinicians' determination of the need for symptomatic therapy for PD. Even when controlling for UPDRS scores, depressed subjects were 83% more likely to be judged as needing symptomatic therapy (for PD) compared to nondepressed subjects. The decision to start PD medications in patients with depression may reflect a clinical judgment to treat depressive symptoms and motor function with PD medications. However, the decision to initiate symptomatic therapy for PD typically focuses on impairments in gait, occupation, and ADLs, and involves patient reported disability and findings on examination. Thus, one explanation for our results is that depressed subjects may have reported more disability for a given level of motor impairment than non-depressed subjects, leading to treatment of motor symptoms rather than treatment of depression.
The main limitation of this study is the absence of a standardized method for establishing depressive diagnoses. We used the GDS-15, a validated screening tool, to assess for clinically important depressive symptomatology and the use of antidepressants or referral for further psychiatric health evaluation as a marker for the treatment of depression. The discrepancy between the screening instrument and clinical care cannot be explained without a diagnostic interview or more formal psychiatric assessment.
Results from this large cohort of subjects with early PD suggest that depression, particularly mild depression, is common early in the disease and is associated with increased disability. Treatment of dPD is limited, but depressive symptoms result in more frequent treatment for motor-related impairment. Future studies in PD may further evaluate the impact of different models of service that have been used in the primary 18 care setting to enhance recognition and management of depression in PD.
